Newsjournal body.qxp - College of Chemistry - University of ...
Newsjournal body.qxp - College of Chemistry - University of ...
Newsjournal body.qxp - College of Chemistry - University of ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Jane Scheiber photo<br />
Chemical Engineering News<br />
by Alexis T. Bell,<br />
Chair<br />
and<br />
Warren and Katharine<br />
Schlinger Distinguished<br />
Pr<strong>of</strong>essor<br />
DEVELOPING OUR<br />
POTENTIAL<br />
Spring is the season <strong>of</strong> renewal and rededication. While budgetary shortfalls remain a subject <strong>of</strong><br />
concern, our faculty has continued to move forward in its efforts to provide our students exciting<br />
educational and research experiences. The bright light just ahead is the Governor’s compact with<br />
the President <strong>of</strong> the <strong>University</strong> <strong>of</strong> California, which promises to restore some <strong>of</strong> the lost state<br />
support. In the meantime, the department’s faculty members continue to gain recognition and to<br />
New Department Chair(s)<br />
After nearly four years <strong>of</strong> service, Pr<strong>of</strong>essor Arup<br />
Chakraborty decided to step down from his position as<br />
department chair. We all owe a debt <strong>of</strong> immense gratitude<br />
to Arup for his tireless efforts during a period <strong>of</strong> budgetary<br />
challenges for the <strong>University</strong> and the department.<br />
Thanks to his fine work, the department has not suffered<br />
and remains exceptionally strong. The <strong>University</strong> has<br />
appointed Pr<strong>of</strong>essor Jeffrey Reimer to become the new<br />
chair; however, he will not assume this position until July<br />
1, 2006, since he plans to take a sabbatical leave during the<br />
2005-2006 academic year. To fill the gap, I have agreed to<br />
serve as chair for the 15-month period between April 1 <strong>of</strong><br />
this year and June 30 <strong>of</strong> next year.<br />
National Medal <strong>of</strong> Science<br />
Pr<strong>of</strong>essor John Prausnitz was selected to receive the<br />
National Medal <strong>of</strong> Science, the nation’s highest honor in<br />
science and technology, in recognition <strong>of</strong> his pioneering<br />
work on the development <strong>of</strong> molecular thermodynamics<br />
and its application to a broad range <strong>of</strong> industrial problems.<br />
The Medal was presented to John at a ceremony hosted by<br />
President George Bush on March 14 at the White House.<br />
While John retired formally from the department on<br />
July 1, 2004, he has been appointed as a Pr<strong>of</strong>essor <strong>of</strong> the<br />
Graduate School and remains highly active in research.<br />
NAE Election<br />
Pr<strong>of</strong>essor Harvey Blanch was elected to the National<br />
Academy <strong>of</strong> Engineering (NAE) and will be inducted into<br />
the Academy next October. This high honor is given in<br />
recognition <strong>of</strong> Harvey’s excellent research and leadership<br />
in the field <strong>of</strong> biochemical engineering. With his<br />
election, the total number <strong>of</strong> NAE members in the department<br />
now stands at six.<br />
Synthetic Biology<br />
Pr<strong>of</strong>essor Jay Keasling will benefit from a<br />
$43 million grant from the Bill and Melinda Gates<br />
Foundation to develop a more affordable approach to the<br />
synthesis <strong>of</strong> artemisinin, an antimalarial drug for use<br />
especially in the third world. Efforts on this project will<br />
be carried out at Berkeley in partnership with the<br />
Institute for OneWorld Health, the first non-pr<strong>of</strong>it pharmaceutical<br />
company in the U.S., and Amyris, a new<br />
biotech firm. OneWorld Health will perform the drug<br />
development and regulatory work to demonstrate the<br />
bioequivalence <strong>of</strong> microbially-produced artemisinin derivative<br />
to the drug’s natural form, whereas Amyris will develop<br />
the process for industrial fermentation and commercialization.<br />
Jay’s work in this area was recently singled<br />
CONQUERING DISEASE.<br />
Jay Keasling’s work on developing a<br />
malaria vaccine has been selected by<br />
Technology Review as one <strong>of</strong> the “10<br />
Emerging Technologies That Will Change<br />
Your World.”<br />
4 BERKELEY COLLEGE OF CHEMISTRY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
coutrtesy Bioengineering